Neuronetics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Neuronetics reported Q3 2026 revenue of $42.0M (vs. $37.3M Q3 2025), with Greenbrook clinics contributing $26.2M (+20.1% YoY) and NeuroStar $15.8M (+1.8% YoY). Net loss narrowed sharply to $1.6M from $9.4M; Adjusted EBITDA swung to $1.9M positive vs. $(4.7)M. Gross margin expanded to 52.2% from 45.9%; operating expenses fell 13% to $21.3M. Full-year 2026 guidance: revenue $160–164M (+7–10%), gross margin 49–50%, operating expenses $92.5–95.5M. Key developments: 510(k) submitted for accelerated TMS (August 2026), distribution agreement signed with Wave Neuro for PTSD indication, EHR/EMR integration with AdvancedMD launched. Cash position $27.9M (including $5.8M restricted); long-term debt $61.8M.
Why this rating
Strong margin expansion and Greenbrook growth offset weak NeuroStar systems; profitability inflection credible but early. Material relative to $129M market cap but still pre-consistent-profit stage.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.